Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Volberding

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
JAMA|February 3, 1989
AIDS-associated non-Hodgkin's lymphoma in San FranciscoL D Kaplan, D I Abrams, E Feigal, et al.
Blood|April 1, 1995
Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcomeL D Kaplan, B Shiramizu, B Herndier, et al.
The New England Journal of Medicine|March 17, 1994
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials GroupW R Lenderking, R D Gelber, D J Cotton, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1989
Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trialJ O Kahn, L D Kaplan, P A Volberding, et al.
Journal of Clinical Pharmacology|January 1, 1996
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcomaD W Northfelt, F J Martin, P Working, et al.
The Journal of Infectious Diseases|June 1, 1989
Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidineM A Jacobson, D I Abrams, P A Volberding, et al.
The Journal of Infectious Diseases|May 6, 1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeS G Deeks, N S Hellmann, R M Grant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1991
Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trialL D Kaplan, J O Kahn, S Crowe, et al.
The New England Journal of Medicine|September 30, 1990
Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trialG S Leoung, D W Feigal, A B Montgomery, et al.
JAMA|September 11, 1987
Suramin therapy in AIDS and related disorders. Report of the US Suramin Working GroupB D Cheson, A M Levine, D Mildvan, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
JAMA|February 3, 1989
AIDS-associated non-Hodgkin's lymphoma in San FranciscoL D Kaplan, D I Abrams, E Feigal, et al.
Blood|April 1, 1995
Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcomeL D Kaplan, B Shiramizu, B Herndier, et al.
The New England Journal of Medicine|March 17, 1994
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials GroupW R Lenderking, R D Gelber, D J Cotton, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1989
Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trialJ O Kahn, L D Kaplan, P A Volberding, et al.
Journal of Clinical Pharmacology|January 1, 1996
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcomaD W Northfelt, F J Martin, P Working, et al.
The Journal of Infectious Diseases|June 1, 1989
Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidineM A Jacobson, D I Abrams, P A Volberding, et al.
The Journal of Infectious Diseases|May 6, 1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeS G Deeks, N S Hellmann, R M Grant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1991
Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trialL D Kaplan, J O Kahn, S Crowe, et al.
The New England Journal of Medicine|September 30, 1990
Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trialG S Leoung, D W Feigal, A B Montgomery, et al.
JAMA|September 11, 1987
Suramin therapy in AIDS and related disorders. Report of the US Suramin Working GroupB D Cheson, A M Levine, D Mildvan, et al.
Pageof 11